Article ID Journal Published Year Pages File Type
7389782 Value in Health Regional Issues 2018 7 Pages PDF
Abstract
Our evidence from Taiwan demonstrated that while sorafenib in combination with other therapeutic approaches might improve treatment outcome when compared with sorafenib monotherapy, its ICER exceeded the WTP threshold and was considered not cost-effective.
Keywords
Related Topics
Health Sciences Medicine and Dentistry Medicine and Dentistry (General)
Preview
Cost-Effectiveness of Sorafenib Monotherapy and Selected Combination Therapy with Sorafenib in Patients with Advanced Hepatocellular Carcinoma
Authors
, , , ,